Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Continuing its ... products, earned three prestigious MarCom Awards for outstanding creative ... received a Platinum MarCom Award, the organization’s top honor, ... in St. Louis held in April of this year. ... than 14,000 attendees. Additionally, Nerium was awarded a Gold ...
(Date:11/26/2014)... 26, 2014 CURE™ magazine ... on December 5, 2014, in San Francisco prior to ... Heroes event will honor clinicians, caregivers, and advocates who ... neoplasms (MPNs). , Special guest speaker Charles Esten, ... cancer journey at the reception. Over a decade ...
(Date:11/26/2014)... Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens, today announced ... Piper Jaffray  26 th Annual Healthcare Conference on December ... at The New York Palace in New York, ... information concerning the Company, its operations, strategies and prospects may ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... Nov. 15 With its warm business climate,and ... the nation,s,leading technology states. Statewide, Florida,s high-tech ... total of 276,400 jobs, according to Florida Cybercities,2007, ... (AeA) using,the most current state data available. ...
... Biosciences,Corporation (Nasdaq: MATK ) announced today that ... has ruled in favor of Martek and upheld,one ... The,modified claims of the patent are narrower than ... that were previously upheld in a,December 2000 Opposition ...
... R&D Head Martin,Mackay, HHS Deputy Secretary Tevi Troy, Former ... FDA/CMS Summit 2007, WASHINGTON, Nov. 15 It,s ... Unfortunately for the biopharma sector and,investors, it,s a record ... grant marketing approval to 18 or fewer new drugs ...
Cached Biology Technology:Florida's Technology Sector Attracting Skilled Workers Needing Homes 2European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed 2European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed 3So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3
(Date:11/7/2014)... Florida , November 6, 2014 ... authentication for better mobile security revolutionizing online transactions.  Companies in ... Alibaba Holdings Ltd. (NYSE: BABA ), Google Inc. ... MSFT ), eBay Inc. (NASDAQ: EBAY ) and ... NXTD and NXTDW), a biometric authentication company focused ...
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... IOF and ESCEO will be staging the ... largest bone meeting in Europe, to be held ... the pre-registration deadline of March 7, 2011 fast ... registration to the 1st IOF-ESCEO Pre-Clinical Symposium (from ...
... Scientists have published results that will forever change the ... replication and the prevention of DNA damage. ... to many problems including cancers. Researchers, funded by the ... Wellcome Trust and working at The University of Nottingham, ...
... Chase, MDA recent study accepted for publication in ... for the first time that maternal fructose intake during ... endocrinology. Fructose is a simple sugar found naturally ... dietary fructose, particularly due to calorically sweetened beverages, are ...
Cached Biology News:8 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2Collisions of protein machines cause DNA replication derailment 2Maternal fructose intake impacts female and male fetuses differently 2
... Convenient platform for tube handling and reagent ... 0.2ml V-bottom tubes - 96 x ... - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations can be ...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
... Recombinant DNA polymerase from Thermus aquaticus expressed ... contamination; 1 tube of 250 units enzyme/tube ... (Low DNA), is the same enzyme as ... through a proprietary separation process to ensure ...
Taq DNA polymerase, 10,000U...
Biology Products: